SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Other Events
Item 8.01. Other Events
On February 14, 2019, SCYNEXIS received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 10 consecutive business days, the closing bid price for SCYNEXIS’s common stock has been equal to or in excess of the $1.00 per share minimum bid price requirement for continued listing, as required by Listing Rule5450(a)(1).Accordingly, the Staff of Nasdaq has determined that SCYNEXIS has regained compliance with Nasdaq Listing Rule5450(a)(1) and the matter is closed.
About SCYNEXIS, Inc. (NASDAQ:SCYX)
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.